Sanara Q2 revenue up 9% to $28.1M; adjusted EBITDA $5.0M; MIMEDX acquisition pending

Sanara MedTech Inc.

Q2 net revenue $28.1M (+9% YoY); gross margin 93%; adjusted EBITDA $5.0M vs $4.7M.
Net loss from continuing ops $0.4M ($0.05/diluted share) vs net income $0.5M ($0.05/share) in Q2 2025.
H1 2026 revenue $55.9M (+14% YoY); adjusted EBITDA $9.3M vs $7.4M.
Cash and equivalents $15.4M; long-term debt $46.5M at June 30, 2026 vs $16.6M and $46.0M at Dec 31, 2025.
Announced transformational acquisition by MIMEDX, expected to combine surgical portfolios; subject to customary closing conditions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.